|Systematic (IUPAC) name|
|Bioavailability||Readily absorbed: 70–90%|
|ATC code||D01 D01|
|Mol. mass||291.43 g/mol|
|(what is this?)|
Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting squalene epoxidase, an enzyme that is part of the fungal cell membrane synthesis pathway. Because terbinafine prevents conversion of squalene to lanosterol, ergosterol cannot be synthesized. This is thought to change cell membrane permeability, causing fungal cell lysis.
Terbinafine is mainly effective on the dermatophyte group of fungi.
As a 1% cream or powder it is used topically for superficial skin infections such as jock itch (Tinea cruris), athlete's foot (Tinea pedis) and other types of ringworm (Tinea corporis). Studies have shown that terbinafine cream works in about half the time required by other antifungals.
Oral 250 mg tablets are often prescribed for the treatment of onychomycosis, a fungal nail infection, typically by a dermatophyte or Candida species. Fungal nail infections are located deep under the nail in the cuticle to which topically applied treatments are unable to penetrate in sufficient amounts. The tablets may, rarely, cause hepatotoxicity, so patients are warned of this and may be monitored with liver function tests. Alternatives to oral administration have been studied. In 2009, results from a clinical study of a new formulation (terbinafine in transfersomes, referred to as TDT-067) for topical treatment of onychomycosis were reported by Celtic Pharma.
It has been found that terbinafine hydrochloride may induce or exacerbate subacute cutaneous lupus erythematosus. Persons with lupus erythematosus should first discuss possible risks with their doctor before initiation of therapy.
Terbinafine first became available in Europe in 1991 and in The United States in 1996. The U.S. Food and Drug Administration has approved the first generic versions of prescription Lamisil (terbinafine hydrochloride) tablets. The remaining patent or exclusivity for Lamisil expired on June 30, 2007.
On September 28, 2007, the FDA stated that Lamisil (terbinafine hydrochloride, by Novartis AG) is a new treatment approved for use by children age 4 and up. The antifungal granules can be sprinkled on a child's food to treat ringworm of the scalp, Tinea capitis.
Many side effects and adverse drug reactions have been reported with oral terbinafine hydrochloride possibly due to its extensive biodistribution and the often extended durations involved in anti-fungal treatment (> 2 months). The following is a comprehensive list of adverse events that are associated with terbinafine use:
- Gastrointestinal problems: Diarrhea, constipation, nausea, sickness, fullness, abdominal pain, indigestion, dyspepsia, gastritis, cholestasis, flatulence, altered stool colour, abdominal muscular pain.
- Central nervous system / neurological problems: Headaches, dizziness, vertigo, light-headedness, decreased concentration levels, paraesthesia (pins and needles)
- Hepatic problems: Raised liver enzymes, liver inflammation (hepatitis), liver damage, liver failure (leading to transplant — or death)
- Immune system problems: Decreased white blood cell counts including pancytopenia, leukopenia, lymphopenia, thrombocytopenia, agranulocytosis, and neutropenia. Auto-immune reactions such as lupus erythematosus
- Sensory problems: Complete loss of taste (ageusia) (sometimes permanent after the treatment), decreased taste (hypogeusia) and distorted taste (dysgeusia) (sometimes permanent after the treatment) often involving a metallic taste sensation and dry mouth. Visual disturbances including blurred vision, green vision and double vision.
- Skin problems: Rashes, hives (urticaria), skin irritation, itching (pruritis), jaundice, Stevens–Johnson syndrome.
- Other side effects: Fatigue, increased heart rate (tachycardia), hair loss, decreased red blood cell count (anemia), muscle pain (myalgia), joint pain (arthralgia).
Terbinafine is sold by the name Lamisil in Argentina, Australia, Belgium, Brazil, Canada, Chile, Croatia, Egypt, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Mexico, New Zealand, Norway, Pakistan (لیمسل), Peru, Romania, Russia, Slovakia, Slovenia, South Africa, Sweden, the United Kingdom, the United States and Venezuela, also sold under the name Corbinal and Terbisil in Turkey, and Undofen in Poland. As a generic oral medication it is sold under the names Sebifin, Tinasil, Terbisil, Terbicor and Tamsil in Australia, whilst the generic topical medication is sold there as SolvEasyTinea and Tamsil. It is also available as a generic medication in the United States, United Kingdom, Belgium, Switzerland and Brazil. In India, Terbinafine hydrochloride is available in topical form under the brand name Sebifin (Ranbaxy Labs), Zimig (GSK Pharma) and mycoCeaze (Progreś Laboratories). MycoVa, developed by Apricus Biosciences, is a topical nail solution of terbinafine and DDAIP which has completed three Phase III studies for the treatment of onychomycosis. Terbinaforce (mankind pharma limited) Tafine (Deurali Janta Pharmaceuticals Pvt Ltd.) in Nepal.
- email@example.com. "What is the most effective treatment for tinea pedis (athlete’s foot)? : The Journal of Family Practice". Jfponline.com. Retrieved 2013-11-09.
- Staff (2009). "Clinical Trials Update". Genetic Engineering & Biotechnology News 29 (8): 58
- Callen JP, Hughes AP, Kulp-Shorten C (September 2001). "Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases". Arch Dermatol 137 (9): 1196–8. doi:10.1001/archderm.137.9.1196. PMID 11559217.
- Reuters, US FDA approves oral granules for scalp ringworm
- "DoubleCheckMD Side Effects". Doublecheckmd.com. 2010-06-16. Retrieved 2013-11-09.
- Stephen McGuire (2008-02-05). "Australian regulators issue warning on Novartis' Lamisil — Medical Marketing and Media". Mmm-online.com. Retrieved 2013-11-09.
- "Terbinafine-1 (Terbinafine Hydrochloride,Lamisil) | Drug Dosage and Side Effects". Healthline.com. 2009-02-27. Retrieved 2013-11-09.